

08-02-2001



101796042

Form PTO-1594

(Rev. 03/01)

OMB No. 0651-0027 (exp. 5/31/2002)

**RECORDATION FORM COVER SHEET
TRADEMARKS ONLY**

 U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

Tab settings ⇨ ⇨ ⇨ ▼ ▼ ▼ ▼ ▼ ▼ ▼

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

(1) Novartis Pharmaceuticals

Corporation and
(2) Novartis Corporation☐ Individual(s)☐ Association☐ General Partnership☐ Limited Partnership☒ Corporation-State☐ OtherAdditional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

☒ Assignment☐ Merger☐ Security Agreement☐ Change of Name☐ Other

Execution Date: 06/22/2001

2. Name and address of receiving party(ies)

Name: Sherwood Services AG

Internal

Address:

Street Address: P.O. Box 1571
Schwertstrasse 9

City: Schaffhausen

State: Switzerland

Zip: CH-8201

☐ Individual(s) citizenship☐ Association☐ General Partnership☐ Limited Partnership☐ Corporation-State☒ Other Corporation-ForeignIf assignee is not domiciled in the United States, a domestic representative designation is attached: ☐ Yes ☒ No

(Designations must be a separate document from assignment)

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or registration number(s):

A. Trademark Application No.(s)

B. Trademark Registration No.(s)

783,928

906,503

1,038,108

1,076,802

672,089

Additional number(s) attached ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Jeffrey S. Boone

Internal Address: Mallinckrodt Inc.

Street Address: P.O. Box 5840

675 McDonnell Boulevard

City: St. Louis

State: MO

Zip: 63134

6. Total number of applications and registrations involved: 5

7. Total fee (37 CFR 3.41): \$ 140.00

☐ Enclosed☒ Authorized to be charged to deposit account

8. Deposit account number:

13-1160

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Jeffrey S. Boone

Name of Person Signing

Signature

2001 JUL 18

Date

Total number of pages including cover sheet, attachments, and document: 5

 Mail documents to be recorded with required cover sheet information to:
 Commissioner of Patent & Trademarks, Box Assignments
 Washington, D.C. 20231

08/02/2001 00000039 131160 783928

01 FC1481

40.00 CH

100.00 CH

TRADEMARK
REEL: 002338 FRAME: 0424

TRADEMARK ASSIGNMENT

THIS TRADEMARK ASSIGNMENT dated as of June 22, 2001 by Novartis Pharmaceuticals Corporation, a Delaware corporation, and Novartis Corporation, a New York corporation (each, an "Assignor" and, collectively, "Assignors"), to Sherwood Services AG, a stock corporation organized under the laws of Switzerland ("Assignee").

BACKGROUND

A. An Assignor owns the United States trademarks, including registrations, identified in Schedule A attached hereto (the "Product Trademarks"); and

B. Assignee desires to acquire Assignors' entire right, title and interest in and to the Product Trademarks.

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged:


1. Each Assignor does hereby sell, transfer, convey and assign unto Assignee such Assignor's entire right, title and interest in and to the Product Trademarks as to which it is indicated as Assignor in Schedule A hereto, together with the goodwill of the business appurtenant thereto and which is symbolized thereby, and the right to renew the trademark registrations included in the Product Trademarks, to be held and enjoyed by Assignee for its own use and benefit and for the use and benefit of its successors and assigns, to be used fully and entirely as said rights would have been held and enjoyed by such Assignor had this assignment not been made.

2. Each Assignor hereby authorizes the Assistant Commissioner of Trademarks of the United States and other empowered officials of the United States Patent and Trademark Office to record the transfer of the registrations for the Product Trademarks, identified in Schedule A, to Assignee as assignee of the appropriate Assignor's entire right, title and interest therein or otherwise as Assignee may direct, in accordance with this Trademark Assignment.

3. This Trademark Assignment may be executed in one or more counterparts, all of which shall be considered one and the same assignment and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties, it being understood that all parties need not sign the same counterpart.


IN WITNESS WHEREOF, each Assignor has caused its proper officer to execute this Assignment effective as of June 22, 2001.

NOVARTIS PHARMACEUTICALS
CORPORATION

By: 
Name: Lawrence S. Perlow


Title: Senior Vice President and
General Manager
Commercial Operations

Sworn to me this 21st day of June, 2001



Notary Public

CARMELA YAUCH
A NOTARY PUBLIC OF NEW JERSEY
My Commission Expires Jan. 3, 2004

NOVARTIS CORPORATION

By: 
Name: WAYNE P. MERKELSON
Title: VP and assoc. gen. Counsel

Sworn to me this 20th day of June, 2001


Notary Public

KATHY M. JONES
Notary Public of New Jersey
My Commission Expires 11/24/2004

Accepted:

ASSIGNEE:

SHERWOOD SERVICES AG

By: F. Brad Salcedo

Name: _____

F. Brad Salcedo

Title: Chief Executive Officer


Notarization below:

Legalization

Seen for legalization of the signature

of Mr. F. Brad Salcedo

Schaffhausen, 12.6.2001



Town Chancery Schaffhausen

Brighte Meier
Brighte Meier

PRODUCT TRADEMARKS

Trademark	Assignor	Registration No.	Registration Date
ANAFRANIL	Novartis Corporation	783,928	January 26, 1965
PAMELOR	Novartis Pharmaceuticals Corporation	906,503	January 26, 1971
RESTORIL	Novartis Pharmaceuticals Corporation	1,038,108	April 20, 1976
RESTORIL	Novartis Pharmaceuticals Corporation	1,076,802	November 8, 1977
TOFRANIL	Novartis Corporation	672,089	January 6, 1959

TRADEMARK